...
首页> 外文期刊>Thrombosis Research: An International Journal on Vascular Obstruction, Hemorrhage and Hemostasis >Suppressing thrombin generation is compatible with the development of atherosclerosis in mice.
【24h】

Suppressing thrombin generation is compatible with the development of atherosclerosis in mice.

机译:抑制凝血酶的产生与小鼠动脉粥样硬化的发展相容。

获取原文
获取原文并翻译 | 示例

摘要

Thrombin has been proposed to play a key role in the development of atherosclerosis, both by promoting fibrin deposition into the atherosclerotic vessel wall and also by signalling through thrombin receptors. Unfortunately, mice homozygous for a deletion of the prothrombin gene (FII) die in utero, making a direct assessment of the role of thrombin during atherogenesis difficult. We have assessed the contribution of thrombin-dependent processes to vascular lipid lesion formation in the atherosclerosis-prone apolipoprotein E (ApoE)-deficient mice by inhibiting thrombin generation with warfarin. ApoE-/- mice were treated with warfarin at a dose that increased the prothrombin time (PT) more than 10-fold (250-375 microg/kg body weight/day) for 12 weeks from the age of 12 weeks onwards. The extent and composition of the vascular lipid lesions that developed were assessed using oil red O to measure neutral lipid in the vessel wall and quantitative immunofluoresence to measure fibrin(ogen) levels as well as macrophage and smooth muscle cell numbers. Mice treated with warfarin developed lesions both in the aortic sinus and the descending aorta to the same degree as mice receiving no treatment (28,351+/-350 microm2/mouse treated with warfarin versus 27,952+/-750 micro2/control mouse; P = .86). However, the amount of fibrin(ogen) deposited in the vessel wall was decreased by more than 60% (34+/-11 arbitrary units in warfarin treated mice versus 92+/-11 arbitrary units in control mice; P < .01). Staining of macrophage and for smooth muscle cell markers was unaltered by treatment with warfarin. We conclude that suppressing thrombin generation does not alter the development of vascular lipid lesions in mice with a severe disorder of lipid metabolism, despite a marked reduction in fibrin(ogen) deposition.
机译:已经提出,凝血酶在动脉粥样硬化的发展中起着关键作用,既可以促进纤维蛋白沉积到动脉粥样硬化的血管壁中,也可以通过凝血酶受体发出信号。不幸的是,纯合子的凝血酶原基因(FII)缺失的小鼠在子宫内死亡,这使得直接评估凝血酶在动脉粥样硬化中的作用变得困难。我们已经评估了凝血酶依赖性过程对易患动脉粥样硬化的载脂蛋白E(ApoE)缺陷小鼠中血管脂质损伤形成的作用,其通过用华法林抑制凝血酶的产生来进行。从12周龄起的12周内,以华法林治疗ApoE-/-小鼠的剂量可使凝血酶原时间(PT)增加超过10倍(250-375μg/ kg体重/天)。使用油红O测量血管壁中性脂质,定量免疫荧光检测纤维蛋白(原)水平以及巨噬细胞和平滑肌细胞数量,评估所形成的血管脂质病变的程度和组成。用华法林治疗的小鼠在主动脉窦和降主动脉中均形成与未接受治疗的小鼠相同的病变程度(用华法林治疗的小鼠为28,351 +/- 350 microm2 /小鼠,而未接受治疗的小鼠为27,952 +/- 750 micro2 / control小鼠; P =。 86)。但是,沉积在血管壁上的纤维蛋白(原)数量减少了60%以上(华法林治疗的小鼠为34 +/- 11个任意单位,对照组为92 +/- 11个任意单位; P <.01) 。通过使用华法林治疗,巨噬细胞和平滑肌细胞标记物的染色没有改变。我们得出的结论是,尽管血纤蛋白(原)沉积明显减少,抑制凝血酶的产生并不会改变具有严重脂质代谢紊乱的小鼠中血管脂质损伤的发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号